FEED

Business Context and Reporting Period

Company: Envue Medical, Inc. (formerly NanoVibronix, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: The Company operates through two segments: NanoVibronix (non-invasive biological response-activating devices for wound healing and pain therapy) and ENvue (enteral feeding systems). Following the ENvue Merger completed in February 2025, the Company is in the initial stage of commercializing ENvue products while managing the NanoVibronix portfolio.

Key Financial Metrics

Note: Financial data is presented in thousands. The significant increase in Net Loss Available to Common Stockholders in Q1 2026 is driven by non-cash deemed dividends related to preferred stock modifications.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 36% to $653,000, primarily due to the removal of the PainShield Ultra product from the market, partially offset by ENvue system sales.
• Gross Margin Deterioration: The Company reported a gross loss of $(55,000) compared to a gross profit of $369,000 in the prior year. This was caused by the loss of high-margin PainShield Ultra sales, inventory write-downs ($122,000), and amortization of intangible assets from the ENvue Merger.
• Operating Expense Increase: Total operating expenses rose 65% to $3,656,000. Selling and marketing expenses increased 121% and General and Administrative (G&A) expenses increased 80%, largely due to a full quarter of ENvue operations, higher professional fees, and severance costs.
• Preferred Stock Activity: Significant non-cash charges impacted the bottom line, including a $16,974,000 deemed dividend from down-round features on Series H Preferred Stock and a $1,097,000 deemed dividend from Series H modifications.

Outlook, Risks, and Contingencies

• Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for the next twelve months. The Company has an accumulated deficit of $112,136,000 and relies on additional financing to fund operations.
• Liquidity: Cash reserves of $2,235,000 are insufficient to fund operations for the next year without further capital raises. The Company plans to fund operations through equity offerings or debt.
• Legal Proceedings: The Company has an accrued arbitration liability of $2,285,000 related to a dispute with Protrade Systems, Inc. regarding a distribution agreement. An appeal was dismissed in March 2026, and the Company is reviewing alternatives.
• Regulatory Issues: The Company identified inaccuracies in its 510(k) application for the PainShield MD Plus product and has requested to withdraw the clearance, halting future sales of that specific product.
• Geopolitical Risks: Operations in Israel and the broader Middle East face risks from ongoing conflicts, which could disrupt trade and manufacturing.

Investor Verification Checklist

• Cash Runway: Verify the timeline and terms of any planned equity or debt financing to address the "substantial doubt" regarding going concern status.
• Revenue Mix: Monitor the transition of revenue reliance from NanoVibronix products to ENvue systems following the removal of PainShield Ultra.
• Arbitration Liability: Confirm the status of the $2.285 million Protrade Systems liability and any potential for further legal costs or settlements.
• Preferred Stock Dilution: Review the terms of Series H and Series X Preferred Stock, specifically the down-round features and conversion rates, which significantly impact common shareholder value.
• Inventory Valuation: Assess the impact of the $122,000 inventory write-down and future write-down risks associated with discontinued products.